October 27, 2020: The data provided thus far simply do not provide enough evidence that there are benefits outweighing the risks for the Reducer, a permanent device.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Diana Zuckerman’s Public Health presentation at FDA MDUFA Meeting, October 27, 2020
October 27, 2020: MDUFA performance goals need to be more patient-centered by including specific metrics pertaining to safety and effectiveness, both pre-market and post-market, and improving patients and consumer advocates’ access to meet with FDA decision-making officials. That will help provide the safeguards that patients and consumers deserve.
Read More »NCHR Statement by Dr. Diana Zuckerman at FDA Covid Vaccine Advisory Committee October 22, 2020
October 22, 2020: It is FDA’s job to make sure that a vaccine has meaningful benefits for the health and lives of most Americans, and especially those most at risk.
Read More »NCHR’s Comments on USPSTF’s Draft Recommendation Regarding Vitamin D Screening
The available evidence is still insufficient to assess the benefits and harms of vitamin D screening for asymptomatic adults.
Read More »NCHR’s Statement at FDA Advisory Committee Meeting on Olanzapine and Samidorphan Combination Tablets
October 9, 2020: Although patients may benefit from olanzapine/samidorphan by experiencing lower weight gain, the risks are too high to justify approval.
Read More »